{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:37:49Z","timestamp":1786617469079,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malaria remains a major global health challenge, and current vaccine strategies provide limited protection. Cabamiquine (CBQ), a Plasmodium translation elongation factor 2 inhibitor, arrests parasite growth during both the liver and blood stages of infection and may promote protective immune responses during controlled parasite infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated whether CBQ-based infection-and-treatment strategies could induce protective immunity in mouse models of liver- and blood-stage Plasmodium infection. Mice received a single oral dose of CBQ during liver-stage infection or CBQ in combination with pyronaridine during blood-stage infection and were subsequently challenged with homologous or heterologous Plasmodium parasites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CBQ treatment during liver-stage infection induced durable protective immunity against homologous and heterologous sporozoite challenge, reduced disease severity, and was associated with liver-resident memory CD8+ T cells. CBQ administered with pyronaridine during blood-stage infection elicited stage-specific immunity that limited parasitemia and protected against severe malaria following homologous or heterologous challenge. Together, these findings demonstrate that CBQ-based infection-and-treatment can combine effective parasite clearance with induction of protective immune responses following both liver- and blood-stage infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CBQ enables in-life chemical inactivation of Plasmodium parasites while promoting long-lasting protective immunity in experimental malaria. These findings provide proof of concept for a simple oral infection-and-treatment strategy that could complement existing malaria vaccination and control approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag402","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:13:27Z","timestamp":1786101207000},"source":"Crossref","is-referenced-by-count":0,"title":["In-life Chemical Inactivation of\n                    <i>Plasmodium<\/i>\n                    Parasites by Cabamiquine Induces Long-Lasting Immune Protection"],"prefix":"10.1093","author":[{"given":"Claudia","family":"Demarta-Gatsi","sequence":"first","affiliation":[{"name":"Global Health R&D of the Healthcare Business of Merck KGaA , Darmstadt ,","place":["Germany"]},{"name":"Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany) , Route de Crassier 1, 1262 Eysins ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-8630","authenticated-orcid":false,"given":"Diana","family":"Moita","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Fontinha","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4231-0036","authenticated-orcid":false,"given":"Raquel","family":"Ventura","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-2879","authenticated-orcid":false,"given":"Helena","family":"Nunes-Caba\u00e7o","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine , Lisboa ,","place":["Portugal"]},{"name":"Faculdade de Medicina da Universidade de Lisboa , Department of Microbiology, Lisbon ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5654-8919","authenticated-orcid":false,"given":"Thomas","family":"Spangenberg","sequence":"additional","affiliation":[{"name":"Global Health R&D of the Healthcare Business of Merck KGaA , Darmstadt ,","place":["Germany"]},{"name":"Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany) , Route de Crassier 1, 1262 Eysins ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-6029","authenticated-orcid":false,"given":"Miguel","family":"Prud\u00eancio","sequence":"additional","affiliation":[{"name":"Gulbenkian Institute for Molecular Medicine , Lisboa ,","place":["Portugal"]},{"name":"Faculdade de Medicina da Universidade de Lisboa , Department of Microbiology, Lisbon ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026081306113604700_jiag402-B1","volume-title":"World Malaria Report 2025: addressing the threat of antimalarial drug resistance","author":"WHO","year":"2025"},{"key":"2026081306113604700_jiag402-B2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","article-title":"Malaria vaccines: a new era of prevention and control","volume":"22","author":"Duffy","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026081306113604700_jiag402-B3","doi-asserted-by":"crossref","first-page":"977472","DOI":"10.3389\/fimmu.2022.977472","article-title":"Five decades of clinical assessment of whole-sporozoite malaria vaccines","volume":"13","author":"Nunes-Cabaco","year":"2022","journal-title":"Front Immunol"},{"key":"2026081306113604700_jiag402-B4","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1038\/s44321-024-00131-0","article-title":"Whole-sporozoite malaria vaccines: where we are, where we are going","volume":"16","author":"Moita","year":"2024","journal-title":"EMBO Mol Med"},{"key":"2026081306113604700_jiag402-B5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","article-title":"Sporozoite immunization: innovative translational science to support the fight against malaria","volume":"22","author":"Richie","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"2026081306113604700_jiag402-B6","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/s41467-024-46270-3","article-title":"Malaria blood stage infection suppresses liver stage infection via host-induced interferons but not hepcidin","volume":"15","author":"Patel","year":"2024","journal-title":"Nat Commun"},{"key":"2026081306113604700_jiag402-B7","doi-asserted-by":"crossref","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","article-title":"PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection","volume":"17","author":"Murphy","year":"2021","journal-title":"PLoS Pathog"},{"key":"2026081306113604700_jiag402-B8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1462-5822.2010.01441.x","article-title":"Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice","volume":"12","author":"Aly","year":"2010","journal-title":"Cell Microbiol"},{"key":"2026081306113604700_jiag402-B9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1084\/jem.20151976","article-title":"Protection against malaria in mice is induced by blood stage-arresting histamine-releasing factor (HRF)-deficient parasites","volume":"213","author":"Demarta-Gatsi","year":"2016","journal-title":"J Exp Med"},{"key":"2026081306113604700_jiag402-B10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(02)09784-2","article-title":"Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum","volume":"360","author":"Pombo","year":"2002","journal-title":"Lancet"},{"key":"2026081306113604700_jiag402-B11","doi-asserted-by":"crossref","first-page":"e64836","DOI":"10.1371\/journal.pone.0064836","article-title":"CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model","volume":"8","author":"Bao","year":"2013","journal-title":"PLoS One"},{"key":"2026081306113604700_jiag402-B12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1186\/s12879-026-13242-5","article-title":"Antimalarial cabamiquine inhibits blood-stage of different field isolates of Plasmodium species","volume":"26","author":"Dembele","year":"2026","journal-title":"BMC Infect Dis"},{"key":"2026081306113604700_jiag402-B13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","article-title":"Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026081306113604700_jiag402-B14","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/s41467-024-51994-3","article-title":"Towards clinically relevant dose ratios for cabamiquine and pyronaridine combination using P. falciparum field isolate data","volume":"15","author":"Maiga","year":"2024","journal-title":"Nat Commun"},{"key":"2026081306113604700_jiag402-B15","doi-asserted-by":"crossref","first-page":"e02181-19","DOI":"10.1128\/AAC.02181-19","article-title":"Preclinical antimalarial combination study of M5717, a Plasmodium falciparum elongation factor 2 inhibitor, and pyronaridine, a hemozoin formation inhibitor","volume":"64","author":"Rottmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081306113604700_jiag402-B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(26)00233-1","article-title":"Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine-pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falciparum malaria (CAPTURE 1): a prospective, multicentre, open-label, phase 2a study","author":"Mombo-Ngoma","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026081306113604700_jiag402-B17","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1016\/j.vaccine.2023.11.023","article-title":"Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines","volume":"41","author":"Moita","year":"2023","journal-title":"Vaccine"},{"key":"2026081306113604700_jiag402-B18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41541-023-00778-9","article-title":"The effect of dosage on the protective efficacy of whole-sporozoite formulations for immunization against malaria","volume":"8","author":"Moita","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026081306113604700_jiag402-B19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.0141-9838.2004.00710.x","article-title":"Hormonal and immunological mechanisms mediating sex differences in parasite infection","volume":"26","author":"Klein","year":"2004","journal-title":"Parasite Immunol"},{"key":"2026081306113604700_jiag402-B20","doi-asserted-by":"crossref","first-page":"e26588","DOI":"10.1371\/journal.pone.0026588","article-title":"Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections","volume":"6","author":"Martin-Jaular","year":"2011","journal-title":"PLoS One"},{"key":"2026081306113604700_jiag402-B21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2875-13-15","article-title":"Simple, sensitive and quantitative bioluminescence assay for determination of malaria pre-patent period","volume":"13","author":"Zuzarte-Luis","year":"2014","journal-title":"Malar J"},{"key":"2026081306113604700_jiag402-B22","doi-asserted-by":"crossref","first-page":"e13124","DOI":"10.1371\/journal.pone.0013124","article-title":"A rapid murine coma and behavior scale for quantitative assessment of murine cerebral malaria","volume":"5","author":"Carroll","year":"2010","journal-title":"PLoS One"},{"key":"2026081306113604700_jiag402-B23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/acsinfecdis.4c00563","article-title":"Drug interaction studies of cabamiquine:ganaplacide combination against hepatic Plasmodium berghei","volume":"11","author":"Gal","year":"2025","journal-title":"ACS Infect Dis"},{"key":"2026081306113604700_jiag402-B24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/acsinfecdis.1c00640","article-title":"Pre-erythrocytic activity of M5717 in monotherapy and combination in preclinical Plasmodium infection models","volume":"8","author":"Fontinha","year":"2022","journal-title":"ACS Infect Dis"},{"key":"2026081306113604700_jiag402-B25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12936-022-04171-0","article-title":"Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside","volume":"21","author":"Khandelwal","year":"2022","journal-title":"Malar J"},{"key":"2026081306113604700_jiag402-B26","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","article-title":"CD8+ T effector memory cells protect against liver-stage malaria","volume":"187","author":"Reyes-Sandoval","year":"2011","journal-title":"J Immunol"},{"key":"2026081306113604700_jiag402-B27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.immuni.2019.09.019","article-title":"Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage infection","volume":"51","author":"Fernandez-Ruiz","year":"2019","journal-title":"Immunity"},{"key":"2026081306113604700_jiag402-B28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/imr.13202","article-title":"Memory CD8+ T cell-mediated protection against liver-stage malaria","volume":"316","author":"Hassert","year":"2023","journal-title":"Immunol Rev"},{"key":"2026081306113604700_jiag402-B29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pt.2019.11.004","article-title":"You shall not pass: memory CD8 T cells in liver-stage malaria","volume":"36","author":"Lefebvre","year":"2020","journal-title":"Trends Parasitol"},{"key":"2026081306113604700_jiag402-B30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2008.00671.x","article-title":"Protective CD8 T cells against Plasmodium liver stages: immunobiology of an \u2018unnatural\u2019 immune response","volume":"225","author":"Overstreet","year":"2008","journal-title":"Immunol Rev"},{"key":"2026081306113604700_jiag402-B31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pt.2013.01.003","article-title":"Infection and treatment immunizations for successful parasite vaccines","volume":"29","author":"Mutapi","year":"2013","journal-title":"Trends Parasitol"},{"key":"2026081306113604700_jiag402-B32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s44321-025-00301-8","article-title":"Complete attenuation of Plasmodium falciparum sporozoites by atovaquone-proguanil","volume":"17","author":"Borrmann","year":"2025","journal-title":"EMBO Mol Med"},{"key":"2026081306113604700_jiag402-B33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081306113604700_jiag402-B34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.immuni.2016.08.011","article-title":"Liver-resident memory CD8(+) T cells form a front-line defense against malaria liver-stage Infection","volume":"45","author":"Fernandez-Ruiz","year":"2016","journal-title":"Immunity"},{"key":"2026081306113604700_jiag402-B35","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1073\/pnas.0805452105","article-title":"Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria","volume":"105","author":"Schmidt","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081306113604700_jiag402-B36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12936-016-1295-5","article-title":"Defining rules of CD8(+) T cell expansion against pre-erythrocytic Plasmodium antigens in sporozoite-immunized mice","volume":"15","author":"Billman","year":"2016","journal-title":"Malar J"},{"key":"2026081306113604700_jiag402-B37","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1056\/NEJMoa2313892","article-title":"Safety and efficacy of immunization with a late-liver-stage attenuated malaria parasite","volume":"391","author":"Lamers","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081306113604700_jiag402-B38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","article-title":"The complexity of protective immunity against liver-stage malaria","volume":"165","author":"Doolan","year":"2000","journal-title":"J Immunol"},{"key":"2026081306113604700_jiag402-B39","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1073\/pnas.1220360110","article-title":"Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity","volume":"110","author":"Bijker","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081306113604700_jiag402-B40","author":"Steel"},{"key":"2026081306113604700_jiag402-B41","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1473-3099(23)00212-8","article-title":"Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in The Netherlands","volume":"23","author":"van der Plas","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026081306113604700_jiag402-B42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","article-title":"Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity","volume":"595","author":"Mwakingwe-Omari","year":"2021","journal-title":"Nature"},{"key":"2026081306113604700_jiag402-B43","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41467-023-40974-8","article-title":"Propensity of selecting mutant parasites for the antimalarial drug cabamiquine","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat Commun"},{"key":"2026081306113604700_jiag402-B44","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1128\/IAI.73.4.2478-2485.2005","article-title":"Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria","volume":"73","author":"Elliott","year":"2005","journal-title":"Infect Immun"},{"key":"2026081306113604700_jiag402-B45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"2026081306113604700_jiag402-B46","doi-asserted-by":"crossref","first-page":"e1000877","DOI":"10.1371\/journal.ppat.1000877","article-title":"Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites","volume":"6","author":"Cockburn","year":"2010","journal-title":"PLoS Pathog"},{"key":"2026081306113604700_jiag402-B47","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/14787210.2015.1031744","article-title":"Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance","volume":"13","author":"von Seidlein","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026081306113604700_jiag402-B48","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1038\/s41467-025-65629-8","article-title":"Tolerance of Plasmodium falciparum mefloquine-resistant clinical isolates to mefloquine-piperaquine with implications for triple artemisinin-based combination therapies","volume":"16","author":"Roesch","year":"2025","journal-title":"Nat Commun"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag402\/70612845\/jiag402.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag402\/70612845\/jiag402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:16:46Z","timestamp":1786616206000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiag402\/8759020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":48,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag402","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"jiag402"}}